SO-29 Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
Year: 2023
Type: conference-abstract
Source: Annals of Oncology
Institutions: Universitat de Vic - Universitat Central de Catalunya, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, KU Leuven, National Cancer Center Hospital East, Memorial Sloan Kettering Cancer Center, Hammersmith Hospital, Imperial College London, Peter MacCallum Cancer Centre, University of Campania "Luigi Vanvitelli", Pfizer (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Celgene, F. Hoffmann-La Roche, Array BioPharma, Genomic Health, Merck KGaA, Taiho Pharmaceutical, Jazz Pharmaceuticals, Les Laboratories Pierre Fabre, Halozyme, Mirati Therapeutics, BeiGene, Incyte, Veracyte, Cancer Research UK, Daiichi-Sankyo, Astellas Pharma, Servier, Novartis Farmacéutica, Ono Pharmaceutical, Ipsen, Sirtex Medical, Genentech, Samsung, EMD Serono, Chugai Pharmaceutical, MSD K.K., Bayer Yakuhin, MSD Italia, Foundation Medicine, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4382811382